Your browser doesn't support javascript.
loading
Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials.
Choi, Ji-Hyun; Shin, Chaewon; Kim, Han-Joon; Jeon, Beomseok.
Afiliação
  • Choi JH; Department of Neurology and Movement Disorder Center, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
  • Shin C; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Kim HJ; Department of Neurology, Chungnam National University Sejong Hospital, Sejong-si, South Korea.
  • Jeon B; Department of Neurology, Chungnam National University College of Medicine, Daejeon, South Korea.
J Neurol ; 269(1): 62-71, 2022 Jan.
Article em En | MEDLINE | ID: mdl-33219422
ABSTRACT
Placebo response in degenerative cerebellar ataxias (CAs) has never been studied despite the large number of randomized controlled trials (RCTs) that have been conducted. In this descriptive review, we aimed to examine the placebo response in patients with CAs. We performed a literature search on PubMed for RCTs on CAs that were published from 1977 to January 2020 and collected data on the changes from the baseline to the endpoint on various objective ataxia-associated clinical rating scales. We reviewed 56 clinical trials, finally including 35 parallel-group studies and excluding 21 cross-over studies. The included studies were categorized as follows (1) studies showing significant improvements in one or more ataxia scales in the placebo groups (n = 3); (2) studies reporting individual placebo responders with improvements in one or more ataxia scales in the placebo groups (n = 5)-the overall proportion of placebo responders was 31.9%; (3) studies showing mean changes in the direction of improvement in at least one ataxia scale in the placebo groups, though not statistically significant (n = 19); (4) studies showing no placebo response in any of the ataxia scales in the placebo groups (n = 4); (5) studies where data on the placebo groups were unavailable (n = 9). This review demonstrated the placebo response in patients with CAs on various objective ataxia scales. Our study emphasizes that the placebo response should be considered when designing, analyzing, and interpreting clinical trials and in clinical practice in CA patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia de Friedreich / Ataxia Cerebelar Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia de Friedreich / Ataxia Cerebelar Idioma: En Ano de publicação: 2022 Tipo de documento: Article